Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Risk Intelligence A/S announces the launch of the new Risk Intelligence System platform

Risk Intelligence A/S (“Risk Intelligence” or "the Company") announces the launch of the new Risk Intelligence System platform, which will significantly improve client and user value and create a solid foundation for growth in annual recurring revenue.MaRisk has been the benchmark for maritime intelligence platforms since 2008 and became the Risk Intelligence System, when PortRisk was added in 2015. Whilst continued development has been done since the last major platform launch in 2016, the Company is now ready to officially unveil the 4th generation to the market after a soft launch from

Announcement regarding managers' transactions in MapsPeople A/S

MapsPeople A/S | Managers transactions Company Announcement No.  34-2023Aalborg, December 6, 2023Announcement regarding managers' transactions MapsPeople A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 of the below transactions related to shares in MapsPeople A/S made by persons discharging managerial responsibilities and/or persons closely related with them. In addition to below transactions, FTWW ApS (closely related to a person discharging managerial responsibilities - Rasmus Mencke, board member in MapsPeople A/S) has signed 84,034 shares.

BioStock: Chordate's CSO comments on the start of the PM009 study

The first patient has now been enrolled in Chordate Medical's open pilot study PM009, which aims to evaluate the effect of the company's migraine treatment Ozilia on patients who do not respond to treatment with CGRP inhibitors and other treatment options. BioStock reached out to the company's Clinical Research & Medical Director, Jan Hermansson, to find out more about the study.Read the full article at biostock.se: https://www.biostock.se/en/2023/12/chordates-cso-comments-on-the-start-of-the-pm009-study/ This is a press release from BioStock - Connecting Innovation & Capital. https://

Fiven ASA announces applicable redemption premium for redeeming its outstanding EUR 70m bonds

As announced on 27 November 2023, Fiven ASA ("Fiven") will redeem its outstanding EUR 70,000,000 senior secured sustainability-linked floating rate bonds with ISIN SE0016075196 (the "Bonds") in advanced on 21 December 2023 (the "Redemption Date").   Fiven has met the sustainability performance target for each relevant KPI on the relevant target observation date (being 21 November 2023) and no sustainability-linked redemption premium shall therefore be paid on the Redemption Date (in accordance with Clause 9.4 (Sustainability-Linked Redemption Premium) of the terms and conditions of

Himalaya Shipping Ltd. (HSHP) – Commercial Update

Hamilton, Bermuda, December 6, 2023 In November 2023, the Company achieved average time charter equivalent (“TCE”) earnings of approximately US$33,200 per day, gross[1]. The Company’s five vessels trading on index-linked time charters earned approximately US$33,800 per day, gross, including average daily scrubber and LNG benefits of approximately US$1,300 per day. The Company’s only vessel trading on a fixed time charter earned US$30,000 per day, gross. The Baltic 5TC Capesize Index averaged US$24,003 during November 2023. The Company has agreed to convert its index linked charters

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseDecember 6, 2023, at 9.30 am EETRepurchase of Outokumpu’s own shares On December 5, 2023, Outokumpu has completed repurchases its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |68,505 |4.2231

STENOCARE A/S: Announcement of Exercise Price of Warrants of Series TO1

STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENONOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided

GARO to divest a small industrial property in Gnosjö for MSEK 12, generating a minor capital gain

At the start of the year, the GARO Electrification business area relocated its operations in Sweden to purpose-designed premises in Hillerstorp. The project included the divestment of a small property in Gnosjö. The property has now been divested at a value of MSEK 12 to ZAL-produkter AB, which is a part of SWEMIX Group. “With the relocation in Sweden and the new facility in Poland, all of the steps of our resolved investments in capacity expansion are now complete, and we are ready for the upcoming expansion to support electrification and energy efficiency in both of our business areas,”

Medivir to present at the Carlsquare Equity Research Investor Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Carlsquare Equity Research Investor Day, today December 6, 2023.   CEO Jens Lindberg will present at 14.30 CET, with focus on the latest developments and the company's future plans. This will include, among other things, the company's rights issue and how it aims to ensure the highest possible speed and momentum in the development program for fostrox with the aim of

WntResearch continues to the second dose group in clinical proof of concept study of Foxy-5

WntResearch today announces that the safety evaluation from the first cohort in the dose-finding part of the proof-of-concept study NeoFox, support continued evaluation of the drug candidate Foxy-5 at an additional higher dose. After the most appropriate dose has been defined in the spring, approximately 80 patients with colon cancer will be treated. An initial efficacy analysis is planned based on data from 20 patients in active treatment and 20 patients in the control group."We are pleased that patient recruitment to the first dose group in the NeoFox study has been completed so quickly

Peab builds adapted housing and a daytime activity center in Harstad

Peab has been commissioned to build adapted housing and a daytime activity center in Harstad. The customer is Harstad Municipality and the contract is worth NOK 114 million.Peab is going to build adapted housing for people with disabilities at Gangsås in Harstad for a gross area of 1,450 m2 and a daytime activity center of 1,350 m2 gross area, divided into two buildings on two floors. The housing will be manned day and night and therefore the buildings will have spaces for personnel. The project also includes considerable work on the surrounding outside area. “We’re very pleased to

CYBER1 - Cyber Security in growth markets - Mangold Insight Analysis

Mangold updates Cyber Security 1 ("CYBER1") after the third quarter of 2023. CYBER1’s revenue increased to EUR 33.9 (30.6) million in the first nine months of the year compared to the same period last year. That represents a growth rate of 10.9 percent. Mangold has chosen to adjust down the growth rate given a lower growth than expected. Gross profit increased to EUR 7.3 (6.0) million during the same period, which corresponds to an increase of 22 percent. EBITDA amounted to EUR -0.76 (-2.61) million, which is a significant improvement over the previous year. However, it is lower than

Systecon announces new CEO and changes to the Board of Directors

STOCKHOLM, SWEDEN – The Systecon Group has embarked on a global growth trajectory and today holds a position as the leading global provider of Analytical Life Cycle Management products, supporting our customers in their quest to provide and ensure cost-effective capabilities. To further stimulate the growth and the global footprint, Systecon today announces upcoming changes to the Management team and changes made to the Board of Directors. New Chief Executive Officer (CEO) Systecon’s Board of Directors is pleased to announce the appointment of Dan Andersson as the new Chief

Oneflow’s monthly ARR update: November 2023

Press release6 December 2023 Oneflow publishes its preliminary monthly ARR. Oneflow had a total ARR (Annual Recurring Revenue) of MSEK 122.8 by the end of November 2023. This is a preliminary number. All financial reports and presentations are available for download on our website here: https://oneflow.com/ir/investors/financial-reports/ For further information, please contact: Anders Hamnes, CEO and FounderMobile: +46 76 788 50 76Email: anders.hamnes@oneflow.com Certified Adviser is FNCA Sweden AB. About Oneflow Oneflow develops, sells, and implements digital

Sivers Photonics, LioniX International, and Chilas B.V. partner to develop narrow-linewidth tunable laser technology for optical communications and optical sensing markets

Sivers Semiconductors AB (“Sivers”) today announced that its subsidiary, Sivers Photonics, has commenced a new partnership with LioniX International and Chilas B.V. to develop and supply a narrow-linewidth integrated O-Band CW Tunable 1310nm laser targeting high growth applications across optical communications and optical sensing sectors.LioniX International, based in Netherlands, is a leading global provider of customised microsystem solutions specialising in silicon nitride photonic integrated circuits (PICs) and MEMS, with expertise covering chip fabrication, electro-optical system

OssDsign’s revenues for the fourth quarter of 2023 are expected to exceed market estimates

OssDsign AB (publ.) today announces that the company expects its revenues for the fourth quarter of 2023 to exceed market expectations. Preliminary total revenues for the period October – November amount to SEK 25.2 million, mainly attributable to a continued strong market performance of the orthobiologics franchise and some extraordinary orders from a large hospital system.According to preliminary and unaudited data, sales of OssDsign Catalyst amounted to SEK 18.8 million during the period of October – November 2023, whereas OssDsign Cranial recorded sales of SEK 6.4 million.   "The

OBSERVE MEDICAL ASA – Last day of trading in subscription rights

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE APPLICABLE. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEE THE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT. Reference is made to the stock exchange announcement published by Observe Medical ASA (the "Company") on 22 November 2023

Transaction in Own Shares

    6 December 2023 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |05/12/2023|+-----------------------------------------------------------

Cell Impact announces final outcome in the company’s partly guaranteed rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN CELL IMPACT AB (PUBL). SEE ALSO THE SECTION “IMPORTANT INFORMATION” BELOW IN THIS DOCUMENT.Today, Cell Impact AB (publ) (Nasdaq First North Growth Market: CI) ("Cell Impact" or the "Company") announces the final outcome of the Company's rights

Wihlborgs welcomes High Court to Börshuset in Malmö

Malmö-based conference operator High Court will conduct restaurant, conference and co-working operations at Malmö Börshus (Börshuset 1) when the building opens its doors in 2025 after comprehensive renovation work.The conference and co-working operator High Court is currently based out of the Court of Appeals’ previous building along Västra hamnkanalen and at Stortorget in central Malmö. Operations in the old court will now expand to Börshuset and include additional service functions that together will occupy the ground floor and half of the first floor. Occupancy is planned for October

BlueNord: Preliminary Production for November 2023

Oslo, 6 December 2023: BlueNord ASA ("BlueNord" or the "Company") has today announced its preliminary production figures for November 2023. The Company had a preliminary production in November of net 24.5 mboepd. The production during the month was stable across all the producing hubs with an overall preliminary operating efficiency above 90%.  BlueNord reiterates its annual production guidance of 24.5 - 25.0 mboepd and expects the full year production for 2023 to be in the upper range of the guidance. This information is subject to disclosure requirements pursuant to section 5-12

Clas Ohlson six-month report 2023/24

Continued strong sales development and improved profitability Second quarter – 1 August to 31 October · Sales increased by 9% to 2,460 MSEK (2,250), an organic growth of 10% and an increase of 10% in comparable units · Online sales increased by 15% to 297 MSEK (258) · Operating profit excluding items affecting comparability totalled 277 MSEK (112). Operating profit amounted to 245 MSEK (112) · The operating margin was 10.0% (5.0) · Net debt/EBITDA (12 months) excl IFRS 16 amounted to 0.0 times (0.8) · Profit after tax totalled 173 MSEK (69) · Earnings per share was 2.

Strong Year On Year Figures And Continued 100 Per Cent Completion Rate As Winter Charter Operations Increase

In November, Norse Atlantic Airways continued to demonstrate strong year on year performance, additionally the airline completed one charter to Antarctica and four ACMI flights. The month saw an average load factor of 61 per cent, representing an increase of 11 percentage points (p.p.) year on year. During November, Norse Atlantic Airways had 48,839 passengers across 242 flights, with 84 per cent of flights arriving within 15 minutes of their scheduled arrival time and a completion rate of 100 per cent.“The month of November represents the full transition to our Winter schedule as we

SmartCraft ASA (SMCRT) - Transactions carried out under the share buy-back program

Please see below information about transactions made under the share buy-back programme for SmartCraft ASA (“SmartCraft”) (Ticker: SMCRT NO). Date on which the share buy-back programme was announced: 28 April 2023. The duration of the buy-back programme: 28 April 2023 until no later than the day before the Issuer's Annual General Meeting in 2024. Size of the buy-back programme: Up to 3,430,446 shares, for a maximum consideration of NOK 85,000,000. From 27 November 2023 until 5 December 2023, SmartCraft has purchased a total of 34,961 own shares at an average price of NOK 21.1521

There are no items matching the current filter
There are no more items matching the current filter
Back to top